Advertisement
Advertisement
GILD
Gilead Sciences Inc
144.40
USDSponsored
-0.77
-0.53%
Mar 17, 16:00 UTC -4
Closed
Pre-Market
144.67
+0.27
+0.19%
GILD Earnings Reports
Positive Surprise Ratio
GILD beat 25 of 40 last estimates.
63%
Next Report
Date of Next Report
Apr 22, 2026
Estimate for Q1 26 (Revenue/ EPS)
$7.05B
/$1.94
Implied change from Q4 25 (Revenue/ EPS)
-11.02%
/+4.30%
Implied change from Q1 25 (Revenue/ EPS)
+5.77%
/+7.18%
Gilead Sciences Inc earnings per share and revenue
On Feb 10, 2026, GILD reported earnings of 1.86 USD per share (EPS) for Q4 25, beating the estimate of 1.84 USD, resulting in a 0.73% surprise. Revenue reached 7.92 billion, compared to an expected 7.85 billion, with a 0.99% difference. The market reacted with a +5.82% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of 1.94 USD, with revenue projected to reach 7.05 billion USD, implying an increase of 4.30% EPS, and decrease of -11.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Mar 16, 2026 For Q4 25
Estimate
-$0.53
Actual
-$0.50
Surprise
+7.29%
Trevi Therapeutics, Inc. Common Stock
Report Date
Mar 17, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.06
Surprise
+40.06%
CytomX Therapeutics, Inc.
Report Date
Mar 16, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.22
Surprise
-130.37%
AC Immune SA
Report Date
Mar 13, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.13
Surprise
+24.29%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Abeona Therapeutics Inc. Common Stock
Report Date
Mar 17, 2026 For Q4 25
Estimate
-$0.36
Actual
-$0.34
Surprise
+6.28%
Artiva Biotherapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.84
Actual
-Surprise
-
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
Kyntra Bio, Inc. Common Stock
Report Date
Mar 16, 2026 For Q4 25
Estimate
-$3.96
Actual
-$3.61
Surprise
+8.90%
Barinthus Biotherapeutics plc - ADR
Report Date
Mar 13, 2026 For Q4 25
Estimate
-$0.40
Actual
-$0.27
Surprise
+33.82%
FAQ
What were Gilead Sciences Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Gilead Sciences Inc reported EPS of $1.86, beating estimates by 0.73%, and revenue of $7.92B, 0.99% above expectations.
How did the market react to Gilead Sciences Inc's Q4 2025 earnings?
The stock price moved up 5.82%, changed from $147.23 before the earnings release to $155.80 the day after.
When is Gilead Sciences Inc expected to report next?
The next earning report is scheduled for Apr 22, 2026.
What are the forecasts for Gilead Sciences Inc's next earnings report?
Based on 10
analysts, Gilead Sciences Inc is expected to report EPS of $1.94 and revenue of $7.05B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement